Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 01 Mar 2023
Ophthalmological Clinical Trials Still Show Sociodemographic Disparities.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Early, virtual palliative care feasible for advanced lung cancer
2.
WHO launches plan for free child cancer medicines
3.
Racial differences seen in epigenetic age acceleration in childhood cancer survivors
4.
Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven
5.
After all, Pulled Myeloma Drug May Help Treat the Illness.
1.
Intelligent Hematopoietic Cell-State Mapping: Transforming Diagnostic Precision and Clinical Decision-Making
2.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
3.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
4.
Women's Health Through Understanding Hematologic Adaptation Across Menstrual and Reproductive Stages
5.
Strategic Applications in Hematology in Clinical Decision-Making
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge